Details for Patent: 8,129,385
✉ Email this page to a colleague
Which drugs does patent 8,129,385 protect, and when does it expire?
Patent 8,129,385 protects TIVICAY PD, TRIUMEQ PD, DOVATO, JULUCA, TIVICAY, and TRIUMEQ, and is included in six NDAs.
Protection for TIVICAY PD has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has one hundred and twenty-five patent family members in thirty-three countries.
Summary for Patent: 8,129,385
| Title: | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
| Abstract: | The present invention is directed to a class of substituted 5-hydroxy-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4a,8a-diaza-anthracene-6,10-di- ones useful as anti-HIV agents. The compounds have the formula: ##STR00001## Z.dbd.O; R.sup.20, R.sup.21, R.sup.22, R.sup.23, R.sup.24 and R.sup.25 independently are hydrogen, C.sub.1-C.sub.8 alkyl, (C.sub.6-C.sub.14)aryl-(C.sub.1-C.sub.8)alkyl, C.sub.6-C.sub.14 aryl, or alkoxy; the stereochemistry of an asymmetric carbon represented by * shows R- or S-configuration, or a mixture thereof; R.sup.X is hydrogen; R.sup.14 is hydrogen or optionally substituted lower alkyl; R.sup.3 is hydrogen; R.sup.1 is hydrogen or lower alkyl; R is halogen; and m is 1, 2 or 3; or a pharmaceutically acceptable salt thereof. |
| Inventor(s): | Johns; Brian Alvin (Research Triangle Park, NC), Kawasuji; Takashi (Osaka, JP), Taishi; Teruhiko (Osaka, JP), Taoda; Yoshiyuki (Osaka, JP) |
| Assignee: | Shionogi & Co., Ltd. (Osaka, JP) GlaxoSmithKline LLC (Philadelphia, PA) |
| Application Number: | 11/919,386 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,129,385 |
|
Patent Claim Types: see list of patent claims | Compound; Composition; |
Drugs Protected by US Patent 8,129,385
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Viiv Hlthcare | TIVICAY PD | dolutegravir sodium | TABLET, FOR SUSPENSION;ORAL | 213983-001 | Jun 12, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Viiv Hlthcare | TRIUMEQ PD | abacavir sulfate; dolutegravir sodium; lamivudine | TABLET, FOR SUSPENSION;ORAL | 215413-001 | Mar 30, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Viiv Hlthcare | DOVATO | dolutegravir sodium; lamivudine | TABLET;ORAL | 211994-001 | Apr 8, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Viiv Hlthcare | JULUCA | dolutegravir sodium; rilpivirine hydrochloride | TABLET;ORAL | 210192-001 | Nov 21, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,129,385
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Japan | 2005-131161 | Apr 28, 2005 |
| Japan | 2005-312076 | Oct 27, 2005 |
| PCT Information | |||
| PCT Filed | April 28, 2006 | PCT Application Number: | PCT/US2006/016604 |
| PCT Publication Date: | November 02, 2006 | PCT Publication Number: | WO2006/116764 |
International Family Members for US Patent 8,129,385
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | E516026 | ⤷ Try a Trial | |||
| Australia | 2006239177 | ⤷ Try a Trial | |||
| Australia | 2006307101 | ⤷ Try a Trial | |||
| Brazil | PI0610030 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
